BI 836880
As of the edition of 20 October 2026, BI 836880 is a drug known only by a code name: stopped in 2020; acts on VEGFA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Code name only
- Registered trials
- 8, 1 stopped early
- Disease areas
- Cancer; Eye; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | P15692 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2016 to now |